Howard Capital Management LLC cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 79.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,488 shares of the medical device company’s stock after selling 9,733 shares during the period. Howard Capital Management LLC’s holdings in DexCom were worth $215,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in DXCM. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in DexCom by 15.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock valued at $758,487,000 after acquiring an additional 1,515,702 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of DexCom by 32.3% during the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock worth $166,077,000 after purchasing an additional 645,534 shares during the period. Legal & General Group Plc acquired a new position in shares of DexCom during the second quarter worth $173,237,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of DexCom by 100.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock worth $159,832,000 after purchasing an additional 1,275,142 shares during the period. Finally, Deutsche Bank AG bought a new stake in shares of DexCom in the second quarter worth $164,035,000. 97.75% of the stock is owned by institutional investors.
Insider Buying and Selling at DexCom
In related news, Director Mark Foletta sold 2,000 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the transaction, the director owned 48,852 shares in the company, valued at $4,168,052.64. The trade was a 3.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the company’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the sale, the insider directly owned 328,970 shares in the company, valued at $25,106,990.40. This trade represents a 7.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 49,313 shares of company stock valued at $3,945,875 over the last three months. 0.28% of the stock is currently owned by corporate insiders.
DexCom Stock Down 1.9%
DexCom stock opened at $86.04 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $92.59. The firm has a 50 day moving average price of $87.61 and a two-hundred day moving average price of $75.86. The firm has a market cap of $32.47 billion, a price-to-earnings ratio of 34.01, a PEG ratio of 1.44 and a beta of 1.48.
DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter in the previous year, the company earned $0.48 EPS. The company’s revenue for the quarter was up 13.1% on a year-over-year basis. Equities analysts predict that DexCom, Inc. will post 2.64 EPS for the current year.
Analyst Ratings Changes
A number of research firms recently weighed in on DXCM. Stifel Nicolaus set a $95.00 price objective on DexCom and gave the company a “buy” rating in a report on Friday, July 31st. TD Cowen reaffirmed a “buy” rating and set a $95.00 target price on shares of DexCom in a research report on Friday, September 18th. Benchmark lifted their target price on DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $105.00 target price (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $94.00 price target on shares of DexCom in a research report on Friday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $92.43.
Get Our Latest Stock Analysis on DexCom
DexCom Profile
DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.
The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.
Featured Stories
- Five stocks we like better than DexCom
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
